Lead asset Stendra® (avanafil) Looks to Build on $25 Million of 2019 Gross Sales
Disruptive pipeline opportunity with topical treatment for Peyronie's disease
Neurotrope Bioscience, Inc. will continue as a separately traded entity with its lead Bryostatin program treating neurodegeneration
Charles S. Ryan, J.D., Ph.D. named President and Chief Executive Officer of Petros
PR Newswire
NEW YORK and MANALAPAN TOWNSHIP, N.J., May 18, 2020